Group 1 - The China Securities 500 Quality Growth Index (930939) increased by 0.59% as of May 23, 2025, with notable gains from Huahai Pharmaceutical (600521) at 8.66%, Betta Pharmaceuticals (300558) at 6.12%, and Xinlitai (002294) at 5.79% [1] - The 500 Quality Growth ETF (560500) rose by 0.75%, with the latest price at 0.95 yuan [1] - The Chief Risk Officer announced a more flexible and precise issuance counter-cyclical adjustment mechanism to better align investment and financing in the capital market [1] Group 2 - Bohai Securities indicated that future market opportunities will depend on incremental changes, suggesting that in case of unexpected downturns due to external risks or investor sentiment, investors should consider counter-cyclical strategies [2] - The report emphasized a "barbell" allocation strategy, focusing on high-dividend and relatively underweighted banking sectors, while also looking for thematic investment opportunities in mergers and acquisitions and new consumption sectors [2] - The 500 Quality Growth Index selects 100 companies with high profitability, sustainable earnings, and strong cash flow from the China Securities 500 Index, providing diverse investment options [2] Group 3 - As of April 30, 2025, the top ten weighted stocks in the China Securities 500 Quality Growth Index accounted for 24.07% of the index, with Chifeng Jilong Gold Mining (600988) being the highest at 3.13% [3] - The top ten stocks include companies like Ninebot (689009), Kaiying Network (002517), and Shenghong Technology (300476), with varying weightings and performance [5]

更多资料加入知识星球：水木调研纪要 关注公众号：水木Alpha May 19, 2025 01:01 PM GMT Zhejiang Huahai Pharmaceutical Co. Ltd. | Asia Pacific Risk Reward Update What's Changed Zhejiang Huahai Pharmaceutical Co. Ltd. (600521.SS) From To Top Pick 600521.SS - Updated Components Investment Thesis Bull Base Bear Scenarios Risk Reward for Zhejiang Huahai Pharmaceutical Co. Ltd. (600521.SS) has been updated. Reason for change We are removing Huahai Pharmaceutical as an analyst Top Pick. There are no changes to our estimates, price target or s ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-061 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的达格列净二甲双胍缓释片的《药品注 册证书》，现将相关情况公告如下： 一、药品的基本情况 1、药品名称及规格： （1）达格列净二甲双胍缓释片（I）：每片含达格列净 5mg（按 C21H25ClO6计） 和盐酸二甲双胍 500mg；每片含达格列净 10mg（按 C21H25ClO6计）和盐酸二甲双 胍 1000mg； （2）达格列净二甲双胍缓释片（III）：每片含达格列净 5mg（按 C21H25ClO6 计）和盐酸二甲双胍 1000mg； 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 ...

Core Viewpoint - Huahai Pharmaceutical (600521) has received the drug registration certificate for Dapagliflozin Metformin Extended-Release Tablets from the National Medical Products Administration, which is intended for improving blood glucose control in adult patients with type 2 diabetes currently treated with Dapagliflozin and Metformin [1] Summary by Categories Product Development - The company has invested approximately 18.31 million yuan in the research and development of this project [1] Market Position - The approval of the drug registration certificate enhances the company's product line, contributing to improved market competitiveness [1] Business Impact - This development is expected to have a positive effect on the company's operational growth [1]

Core Points - The company held its 21st temporary meeting of the 8th Supervisory Board on May 21, 2025, where all three attending supervisors unanimously approved the proposal to open a special account for temporarily supplementing working capital with idle raised funds [1][2] - The company plans to use up to 181 million yuan of idle raised funds to temporarily supplement its working capital, ensuring compliance with regulatory requirements and protecting investors' rights [2] Group 1 - The meeting was legally valid with three supervisors present, meeting the required quorum [1] - The proposal to open a special account for the management of idle raised funds was passed with a unanimous vote of 3 in favor [1][2] - The company will sign a regulatory agreement with the sponsoring institution and the bank to oversee the storage and use of the raised funds [2]

第八届监事会第二十一次临时会议决议公告 浙江华海药业股份有限公司 监事会 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第八届监事会第二十一次临时 会议于二零二五年五月二十一日在公司四楼会议室以通讯方式召开。会议应到会 监事三人，实际到会监事三人，符合召开监事会会议的法定人数。会议由监事王 虎根先生主持。会议程序符合《公司法》《证券法》及《公司章程》的规定，会议 合法有效。会议审议并一致通过了如下议案： 一、审议通过了《关于开立闲置募集资金暂时补充流动资金专用账户的议案》 表决情况：同意：3 票；反对：0 票；弃权：0 票。 会议决议：公司已于 2025 年 4 月 28 日召开的第八届董事会第三次会议、第 八届监事会第三次会议审议通过公司使用不超过 1.81 亿元的闲置募集资金暂时补 充流动资金事项。为规范公司暂时用于补充流动资金的闲置募集资金的使用与管 理，保护投资者的权益，根据《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》《上海证券交易所上市公司 ...

表决情况：同意：9 票；反对：0 票；弃权：0 票。 会议决议：公司已于 2025 年 4 月 28 日召开的第八届董事会第三次会议审议 通过公司使用不超过 1.81 亿元的闲置募集资金暂时补充流动资金事项。为规范公 司暂时用于补充流动资金的闲置募集资金的使用与管理，保护中小投资者的权益， 董事会同意公司向银行申请开立闲置募集资金暂时补充流动资金的专项存储账户， 用于该部分闲置募集资金的存放、管理和使用。同时，董事会授权公司经营管理层 或其授权代表全权办理开立本次闲置募集资金暂时补充流动资金专用账户、签署募 集资金监管协议等事宜。 特此公告。 浙江华海药业股份有限公司 董事会 股票简称：华海药业 股票代码：600521 公告编号：临 2025-059 号 债券简称：华海转债 债券代码：110076 浙江华海药业股份有限公司 第八届董事会第三十六次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第八届董事会第三十六次临时 会议于二零二五年五月二十一日上午九点以通讯 ...

沪指5月20日上涨0.38%，申万所属行业中，今日上涨的有27个，涨幅居前的行业为美容护理、综合， 涨幅分别为2.50%、2.12%。医药生物行业今日上涨1.64%。跌幅居前的行业为国防军工、煤炭，跌幅分 别为0.50%、0.33%。 资金面上看，两市主力资金全天净流出10.37亿元，今日有18个行业主力资金净流入，电子行业主力资 金净流入规模居首，该行业今日上涨0.71%，全天净流入资金26.73亿元，其次是医药生物行业，日涨幅 为1.64%，净流入资金为15.55亿元。 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002365 | 永安药业 | -0.71 | 36.51 | -16324.52 | | 688266 | 泽璟制药 | 3.88 | 3.14 | -6829.52 | | 300401 | 花园生物 | -0.52 | 3.64 | -5971.33 | | 600789 | 鲁抗医药 | 0.56 | 12.15 | -3731.74 | | 600252 | 中恒集团 ...

Market Overview - The Shanghai Composite Index closed at 3380.45 points, above the five-day moving average, with a gain of 0.38% [1] - The total trading volume of A-shares reached 752.206 billion yuan [1] Stocks Performance - A total of 730 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Fulejia (Code: 301371) with a deviation rate of 8.24% and a daily increase of 12.17% [1] - Huahai Pharmaceutical (Code: 600521) with a deviation rate of 7.56% and a daily increase of 10.00% [1] - Aofei Entertainment (Code: 002292) with a deviation rate of 7.46% and a daily increase of 10.02% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the five-day moving average include: - Fulejia: Latest price 36.05 yuan, five-day moving average 33.31 yuan [1] - Huahai Pharmaceutical: Latest price 15.62 yuan, five-day moving average 14.52 yuan [1] - Aofei Entertainment: Latest price 9.77 yuan, five-day moving average 9.09 yuan [1] - Other notable stocks with high daily turnover rates include: - Huifeng Diamond (Code: 839725) with a daily increase of 9.56% and a turnover rate of 14.77% [1] - Beiningmei (Code: 002570) with a daily increase of 10.07% and a turnover rate of 22.33% [1]

"聪明钱"流向曝光！暗盘资金破解主力操盘密码>> 创新药概念震荡走高，一品红（300723）、三生国健、亚泰集团（600881）、华海药业（600521）涨 停，泰格医药（300347）、舒泰神（300204）、科伦药业（002422）等涨幅居前。 ...